Stock EYEN EYENOVIA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Eyenovia, Inc.

Equities

EYEN

US30234E1047

Market Closed - Nasdaq
Other stock markets
 01:30:00 06/07/2024 am IST 		5-day change 1st Jan Change
0.872 USD +13.50% Intraday chart for Eyenovia, Inc. +46.78% -58.08%
01/07 NovaBay Pharmaceuticals, Eyenovia Begin Co-Promotion Deal Activities MT
01/07 NovaBay Pharmaceuticals, Inc. and Eyenovia, Inc. Commence Co-Promotion Activities CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
NovaBay Pharmaceuticals, Eyenovia Begin Co-Promotion Deal Activities
MT
NovaBay Pharmaceuticals, Inc. and Eyenovia, Inc. Commence Co-Promotion Activities
CI
Eyenovia Announces Pricing of $5M Registered Direct Offering
AQ
Transcript : Eyenovia, Inc., Q1 2024 Earnings Call, May 15, 2024
Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
AQ
Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th
AQ
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
AQ
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension
CI
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives
MT
Eyenovia Explores Wide Range of Strategic Alternatives
CI
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
AQ
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
AQ
Transcript : Eyenovia, Inc., Q4 2023 Earnings Call, Mar 18, 2024
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
AQ
North American Morning Briefing : Investors -2-
DJ
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment, Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
AQ
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
AQ
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EYEN Stock
  4. News Eyenovia, Inc.